ABBOTT LABORATORIES

ISIN: US0028241000 WKN: 002824100

Overview




| General attributes | | | | |
|--------------------|---------------------------------------|--|--|--|
| ISIN | US0028241000 | | | |
| Symbol | ABT | | | |
| Exchange | NYSE | | | |
| Currency | USD | | | |
| Sector | Chemical / Pharmaceutical / Health | | | |
| Security type | Stock | | | |
| Market cap (m) | 171,816 EUR | | | |
| Benchmark | S&P 500 | | | |
| | | | | |

| Market data | |
|-------------------|------------------|
| Bid (Bid size) | 105.90 USD (100) |
| Ask (Ask size) | 106.92 USD (100) |
| Open | 106.52 USD |
| High | 106.60 USD |
| Low | 105.79 USD |
| Close (prev. day) | 105.64 USD |
| VWAP | 106.149625 USD |
| Volume (pcs) | 6,556,396 |
| Trading volume | 695,914,163.64 |
| Number of trades | 71,295 |
| Last size | - |

| Futures and Options | |
|----------------------------|----|
| Related Futures | 15 |
| Related Options | - |

| PDF Downloads | |
|-------------------------------------|--|
| Company report: ABBOTT LABORATORIES | |



Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

| on instrument | on sector | on market | |
|---------------|--------------------|-----------------------|----------|
| Date | | Headline | Download |
| 2024/04/26 | 80. J.S. 821 TS | Global Equity Ratings | |
| 2024/04/03 | 8. LØ Ø1 1% | Global Equity Ratings | |
| 2024/03/13 | 8. J.B 81 TS | Global Equity Ratings | |
| 2024/02/22 | 8. LØ Ø1 1% | Global Equity Ratings | |
| 2024/02/14 | 8. L2 27 TS | Global Equity Ratings | .≛. |




Details

| 2024/05/07 22:00 | :01 | |
|-------------------------|-----|--------------|
| Price | | |
| 106.17 USD | | |
| Difference | 0 | 0.50% (0.53) |

| General attributes | | | | |
|--------------------|---------------------------------------|--|--|--|
| ISIN | US0028241000 | | | |
| Symbol | ABT | | | |
| Exchange | NYSE | | | |
| Currency | USD | | | |
| Sector | Chemical / Pharmaceutical / Health | | | |
| Security type | Stock | | | |
| Market cap (m) | 171,816 EUR | | | |
| Benchmark | S&P 500 | | | |
| | | | | |

| Market data | |
|-------------------|------------------|
| Bid (Bid size) | 105.90 USD (100) |
| Ask (Ask size) | 106.92 USD (100) |
| Open | 106.52 USD |
| High | 106.60 USD |
| Low | 105.79 USD |
| Close (prev. day) | 105.64 USD |
| VWAP | 106.149625 USD |
| Volume (pcs) | 6,556,396 |
| Trading volume | 695,914,163.64 |
| Number of trades | 71,295 |
| Last size | - |

| Performance and Risk | | | | | | |
|----------------------|----------|--------|---------|--|--|--|
| | 6m 1Y 3Y | | | | | |
| Perf (%) | +11.99% | -4.57% | -10.74% | | | |
| Perf (abs.) | +11.37 | -5.09 | -12.78 | | | |
| Beta | 0.50 | 0.43 | 0.72 | | | |
| Volatility | 17.07 | 18.17 | 22.51 | | | |



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

| Price data | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 105.98 USD (4,352,450) |
| Ø price 30 days Ø volume 30 days (pcs.) | 108.86 USD (5,289,576) |
| Ø price 100 days Ø volume 100 days (pcs.) | 112.24 USD (5,484,967) |
| Ø price 250 days Ø volume 250 days (pcs.) | 106.56 USD (5,285,224) |
| YTD High date | 121.64 USD (2024/03/08) |
| YTD Low date | 104.25 USD (2024/04/17) |
| 52 Weeks High date | 121.64 USD (2024/03/08) |
| 52 Weeks Low date | 89.67 USD (2023/10/12) |

| All listings for ABBOTT LABORATORIES | | | | | |
|--------------------------------------|----------------|-------|-----------|-----------------------|------------------|
| Exchange 🖨 | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/05/ 08 | 09:23 | 99.08 EUR | 0.01 | 3 |
| Vienna Stock Exchange | 2024/05/ 08 | 09:05 | 98.97 EUR | 0.00 | 1 |
| Tradegate | 2024/05/ 08 | 09:32 | 99.08 EUR | 0.01 | 5 |
| Stuttgart | 2024/05/ 08 | 08:02 | 98.52 EUR | 0.00 | 1 |
| SIX Swiss Exchange | 2024/02/ | 17:31 | 93.00 CHF | 0.00 | 1 |



| | 19 | | | | |
|--------------------------|----------------|-------|------------|--------|--------|
| NYSE | 2024/05/ 07 | 22:00 | 106.17 USD | 695.91 | 71,295 |
| Munich | 2024/05/ 08 | 08:05 | 98.57 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/04/ 26 | 15:47 | 106.77 USD | 0.00 | 1 |
| Hanover | 2024/05/ 08 | 08:01 | 98.48 EUR | 0.00 | 1 |
| Hamburg | 2024/05/ 08 | 08:01 | 98.48 EUR | 0.00 | 1 |
| Frankfurt | 2024/05/ 08 | 08:05 | 98.48 EUR | 0.00 | 1 |
| Duesseldorf | 2024/05/ 08 | 09:31 | 98.54 EUR | 0.00 | 2 |
| Berlin | 2024/05/ 08 | 09:50 | 98.88 EUR | 0.00 | 3 |



Company profile

Company Logo



Contact Details

ABBOTT LABORATORIES

_ _

100 Abbott Park Road - 60064-6400 Abbott Park

Telefon: +1-224-667-6100

Fax: + E-mail: -

PDF Downloads

Company report: ABBOTT LABORATORIES



Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Members of Management Board

.

| Robert Alpern | Member of Board of Directors |
|-------------------------------|---------------------------------|
| Sally Blount | Member of Board of Directors |
| Claire Babineaux- Fontenot | Member of Board of Directors |
| Daniel Starks | Member of Board of Directors |
| Darren McDew | Member of Board of Directors |
| John Stratton | Member of Board of Directors |
| Michael O'Grady | Member of Board of Directors |
| Michael Roman | Member of Board of Directors |
| Michelle Kumbier | Member of Board of Directors |
| Nancy McKinstry | Member of Board of Directors |
| Paola Gonzalez | Member of Board of Directors |
| Robert B. Ford | Chairman of Managing Board |
| Andrea F. Wainer | Member of Executive Committee |
| Daniel Salvadori | Member of Executive Committee |
| Hubert L. Allen | Member of Executive Committee |
| Lisa D. Earnhardt | Member of Executive Committee |
| Mary K. Moreland | Member of Executive Committee |
| Robert E. Funck, Jr. | Member of Executive Committee |
| | |



